Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment for relapsed-refractory MM (rrMM). This phase II study evaluated bendamustine plus bortezomib and dexamethasone (BVD) administered over six 28-day cycles and t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Offidani, M, Corvatta, L, Maracci, L, Liberati, A M, Ballanti, S, Attolico, I, Caraffa, P, Alesiani, F, Caravita di Toritto, T, Gentili, S, Tosi, P, Brunori, M, Derudas, D, Ledda, A, Gozzetti, A, Cellini, C, Malerba, L, Mele, A, Andriani, A, Galimberti, S, Mondello, P, Pulini, S, Coppetelli, U, Fraticelli, P, Olivieri, A, Leoni, P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3880441/
https://ncbi.nlm.nih.gov/pubmed/24270324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2013.58
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak